Our content is fact checked by our senior editorial staff to reflect accuracy and ensure our readers get sound information and advice to make the smartest, healthiest choices.
We adhere to structured guidelines for sourcing information and linking to other resources, including scientific studies and medical journals.kickstarting our diet and workout routines. But while more time in the gym and counting calories may work for some, shedding stubborn pounds can be more difficult for others. That's whereoften come in. Novo Nordisk's diabetes drug Ozempic and its sister drug for weight loss, Wegovy, are the biggest names in the space right now—but the company isn't stopping there.
However, as of right now, the company is benefiting from Amycretin's stellar performance. After study results were announced, Novo Nordisk shares jumped 8 percent, Reuters reported. "We believe this data release is the primary driver for the shares," Barclays analysts said in a note, per theNovo Nordisk is also testing amylin in its weight-loss combination therapy CagriSema, which combines semaglutide with an amylin analog called cagrilintide. The treatment is being studied in a phase 3 trial, where it has shown greater weight loss and blood sugar control effects for patients with diabetes than those treated with one drug or the other.
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: CNBC - 🏆 12. / 72 Read more »
Source: TODAYshow - 🏆 389. / 55 Read more »